A Non-interventional Study to Follow and Evaluate Patients With Advanced NSCLC Who Are Treated in Second Line Setting With Tarceva (Erlotinib) in a "Real Life" Clinical Setting
N/A
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Non-Small Cell Lung Cancer
Both
Non-Small Cell Lung Cancer
Trial Information
A Non-interventional Study to Follow and Evaluate Patients With Advanced NSCLC Who Are Treated in Second Line Setting With Tarceva (Erlotinib) in a "Real Life" Clinical Setting
Inclusion Criteria:
- Adult patients, >/= 18 years of age
- Recurrent or metastatic, Stage III or IV Non-Small Cell Lung Cancer (NSCLC)
- Measurable disease (RECIST criteria)
- ECOG performance status 0-2
- Prior course of standard systemic chemotherapy
Exclusion Criteria:
- Contra-indications to treatment with Tarceva
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Efficacy in routine daily oncology practice: tumor assessments, European Cooperative Oncology Group (ECOG) performance status, quality of life (Lung Cancer Symptom Scale), as available
Outcome Time Frame:
44 months
Safety Issue:
No
Principal Investigator
Clinical Trials
Investigator Role:
Study Director
Investigator Affiliation:
Hoffmann-La Roche
Authority:
Belgium: Ministry of Social Affairs, Public Health and the Environment
Study ID:
ML21474
NCT ID:
NCT01161173
Start Date:
April 2008
Completion Date:
August 2012
Related Keywords:
- Non-Small Cell Lung Cancer
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
Name | Location |
|---|
